Paxlovid Boceprevir Entèmedyè CAS 565456-77-1 Essay ≥99.0%
Pwovizyon Komèsyal PF-07321332 Paxlovid ki gen rapò ak Entèmedyè ak kalite siperyè
L-tèt-Leucine (H-Tle-OH) CAS 20859-02-3
Karonic Anhydride CAS 67911-21-1
(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic asid Methyl Ester Hydrochloride 565456-77-1
Methyl (S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate CAS 328086-60-8
6,6-Dimethyl-3-azabicyclo[3.1.0]hexane CAS 943516-54-9
Non Chimik | (1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic asid Methyl Ester Hydrochloride |
Sinonim | Methyl (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate Hydrochloride |
Nimewo CAS | 565456-77-1 |
Nimewo CAT | RF-PI318 |
Estati Stock | Nan Stock, Pwodiksyon Echèl Jiska Tòn |
Fòmil molekilè | C9H15NO2.ClH |
Pwa molekilè | 205.683 |
Mak | Ruifu Chimik |
Atik | Espesifikasyon |
Aparans | Poud blan pou blan |
Idantifikasyon A | IR: Menm jan ak sibstans referans |
Idantifikasyon B | Tan Retansyon: Menm jan ak Sibstans Referans |
Enantiomère | ≤0.15% |
Enpurte ki gen rapò (pa HPLC) | |
Enkoni Enpurte | ≤0.20% |
Enpurte total | ≤1.0% |
Dlo | ≤0.50% |
Rezid sou ignisyon | ≤0.10% |
Metal lou | ≤20ppm |
Esè | ≥99.0% |
Tès Creole | Enterprise Standard |
Itilizasyon | Entèmedyè nan PF-07321332 Paxlovid (CAS 2628280-40-8) ak Boceprevir (CAS 394730-60-0) |
Pake: Boutèy, sak papye aliminyòm, tanbou katon, 25kg / tanbou, oswa selon kondisyon kliyan an.
Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè, imidite ak ensèk nuizib.
(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Asid Methyl Ester Hydrochloride (CAS 565456-77-1) se yon dérivé azabicyclohexane ki itilize nan preparasyon epatit C. viris (HCV) NS3 serine inibitè proteaz.Li se entèmedyè PF-07321332 Paxlovid (CAS 2628280-40-8) ak Boceprevir (CAS 394730-60-0).PF-07321332 se yon inibitè ki pisan epi ki aktif oralman SARS-CoV 3C-tankou proteaz (3CLPRO).PF-07321332 vize viris SARS-CoV-2 epi li ka itilize pou rechèch COVID-19.Boceprevir (INN, non komèsyal Victrelis) se yon inibitè pwoteaz yo itilize kòm yon tretman pou epatit C jenotip 1. Li mare nan sit aktif HCV ki pa estriktirèl 3 NS3 (HCV).Li te devlope pa Schering-Plough, men se kounye a ap devlope pa Merck depi Schering te akeri nan 2009. Li te apwouve pa FDA a sou 13 me 2011.